1
|
Schrenk C, Fetz V, Vallet C, Heiselmayer C, Schröder E, Hensel A, Hahlbrock A, Wünsch D, Goesswein D, Bier C, Habtemichael N, Schneider G, Stauber RH, Knauer SK. TFIIA transcriptional activity is controlled by a 'cleave-and-run' Exportin-1/Taspase 1-switch. J Mol Cell Biol 2018; 10:33-47. [PMID: 28992066 DOI: 10.1093/jmcb/mjx025] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Accepted: 07/09/2017] [Indexed: 12/24/2022] Open
Abstract
Transcription factor TFIIA is controlled by complex regulatory networks including proteolysis by the protease Taspase 1, though the full impact of cleavage remains elusive. Here, we demonstrate that in contrast to the general assumption, de novo produced TFIIA is rapidly confined to the cytoplasm via an evolutionary conserved nuclear export signal (NES, amino acids 21VINDVRDIFL30), interacting with the nuclear export receptor Exportin-1/chromosomal region maintenance 1 (Crm1). Chemical export inhibition or genetic inactivation of the NES not only promotes TFIIA's nuclear localization but also affects its transcriptional activity. Notably, Taspase 1 processing promotes TFIIA's nuclear accumulation by NES masking, and modulates its transcriptional activity. Moreover, TFIIA complex formation with the TATA box binding protein (TBP) is cooperatively enhanced by inhibition of proteolysis and nuclear export, leading to an increase of the cell cycle inhibitor p16INK, which is counteracted by prevention of TBP binding. We here identified a novel mechanism how proteolysis and nuclear transport cooperatively fine-tune transcriptional programs.
Collapse
Affiliation(s)
- Christian Schrenk
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Verena Fetz
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Cecilia Vallet
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Christina Heiselmayer
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Elisabeth Schröder
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Astrid Hensel
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Angelina Hahlbrock
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Désirée Wünsch
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Dorothee Goesswein
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Carolin Bier
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Negusse Habtemichael
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Günter Schneider
- University Hospital Klinikum rechts der Isar, II. Medizinische Klinik, Technical University München, 81675 Munich, Germany
| | - Roland H Stauber
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Shirley K Knauer
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| |
Collapse
|